Clostridium Difficile Infection
Clostridium Difficile Infection - Related Videos
02:27
Establishing a Mouse Model of Clostridium difficile Infection
0 Views •
2026
Source: Winston, J. A., et al. Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291. J. Vis. Exp. (2016)This video demonstrates the procedure for inoculating antibiotic-pretreated mice with Clostridium difficile spores to establish a murine model of infection for studying pathogenesis and host responses.
03:08
Quantification of Clostridium difficile in Fecal Samples from an Infected Mouse Model
0 Views •
2026
Source: Winston, J. A. et al. Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291. J. Vis. Exp. (2016)This video demonstrates the quantification of Clostridium difficile in fecal samples from an infected mouse model using selective culture techniques. It outlines the procedures for sample collection, anaerobic processing, serial dilution, and colony enumeration to assess bacterial colonization and host-pathogen interactions.
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
0 Views •
Cited by 4 •
2017
Antibiotic efficacy is most commonly determined by conducting killing kinetic studies and measuring colony forming units (CFUs). By integrating scanning electron microscopy (SEM) with these standard methods, we can distinguish the pharmacological effects of treatment between different antibiotics.
11:13
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
0 Views •
Cited by 100 •
2013
Clostridium difficile is a pathogenic bacterium that is a strict anaerobe and causes antibiotic associated diarrhea (AAD). Here, methods for isolating, culturing and maintaining C. difficile vegetative cells and spores are described. These techniques necessitate an anaerobic chamber, which requires regular maintenance to ensure proper conditions for optimal C. difficile cultivation.
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
0 Views •
Cited by 53 •
2016
This protocol outlines the cefoperazone mouse model of Clostridium difficile infection (CDI) using a clinically-relevant and genetically-tractable strain, R20291. Emphasis on clinical disease monitoring, C. difficile bacterial enumeration, toxin cytotoxicity, and histopathological changes throughout CDI in a mouse model are detailed in the protocol.
FAQs
Spores can survive in the environment, allowing them to remain a potential source of exposure beyond the initial intestinal event. After reaching the intestine, they may colonize the colon and support toxin production. This environmental persistence explains why clinical management must address not only the affected patient but also measures intended to limit transmission and reduce recurrence.
Antibiotic exposure can disrupt the normal gut microbiota, changing the intestinal environment in a way that favors C. difficile colonization. This relationship links antimicrobial use with the development of disease without making antibiotics the direct source of the bacterial toxins. Clinically, the history of recent antibiotic exposure provides important context when evaluating compatible symptoms.
The toxins damage epithelial cells lining the colon and trigger inflammation. That combination connects bacterial activity with manifestations such as diarrhea and abdominal pain rather than treating symptoms as isolated findings. In clinical interpretation, toxin-mediated injury also helps explain why testing for toxins or toxin-producing organisms is relevant when symptoms suggest infection.
Neither clinical symptoms nor laboratory findings should be considered in isolation when evaluating suspected disease. Symptom assessment identifies the compatible illness, while stool testing can detect toxins or organisms capable of producing toxins. Combining these sources of information supports a more clinically grounded assessment and helps distinguish relevant infection from an isolated laboratory observation.
Clinical management begins with assessing compatible symptoms and using stool testing to evaluate toxins or toxin-producing organisms. Once infection is identified, treatment is directed toward resolving the disease, while infection-control measures aim to limit spread. The overall approach also considers recurrence, because successful care includes reducing the likelihood that illness returns after the initial episode.
This infection provides a clinical model for understanding how antimicrobial exposure, microbiome disruption, environmental spore survival, and bacterial toxins can combine to produce disease. Its healthcare relevance extends beyond diagnosis because infection-control measures are needed to prevent transmission, while treatment strategies must address disease resolution and the possibility of recurrence in clinical settings.